view low-bandwidth site

Wave 80 to present poster at multiple sclerosis meeting

Exploring new methods of optimizing therapy.

San Francisco, California, January 3, 2009. Wave 80's Senior Director of Applied Cell Physiology, Dr. Andrew Arsham, will present a poster at the upcoming Keystone Symposium on Multiple Scleroris, to be held in Santa Fe, New Mexico from January 21-26, 2009, the company announced today.

Dr. Arsham's poster will report on novel applications of microfluidics for measuring cell adhesion processes. The work is relevant to the class of therapeutic agents for the treatment of MS and other autoimmune disorders known as specific adhesion molecule inhibitors. The humanized monoclonal antibody Tysabri, the best studied of this class, blocks the interaction of a molecule on the surface of immune cells called an integrin with its binding partner on blood vessel walls.

The meeting is the first ever Keystone Symposium to be devoted to multiple sclerosis. Dr. Arsham's poster is entitled "Microfluidics-based synthetic microvasculature for for measurement and modeling of cell adhesion."

About Wave 80

Wave 80 Biosciences is a research-driven medical technologies company developing innovative molecular assay methods, novel techniques for leukocyte analysis and fractionation, and next-generation clinical laboratory testing systems. The centerpiece of Wave 80’s product pipeline is the EOSCAPE family of high-performance, compact-form-factor systems for measurement of high-clinical-value biomarkers in peripheral blood. Wave 80 is headquartered in San Francisco, California.